Thalidomide administration for the treatment of resistant plasma cell leukemia.
Tsiara
Stavroula
S
Hematology Unit, University of Ioannina, Medical School, Ioannina, Grece.
Chaidos
Aristeidis
A
Kapsali
Helen
H
Tzouvara
Evagelia
E
Bourantas
Konstantinos L
KL
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000627:therapeutic use; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007952:Leukemia, Plasma Cell / Q000188:drug therapy* / Q000209:etiology; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000628:therapy; D013792:Thalidomide / Q000009:adverse effects / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D020533:Angiogenesis Inhibitors; D013792:Thalidomide